Pendal Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Pendal Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$86M	Buy	297,723 +425	+0.1%	+$130K	0.74%	48
2022 Q3	$86.1M	Sell	297,298 -61,498	-17%	-$17.7M	0.84%	41
2022 Q2	$101M	Buy	358,796 +356,424	+15,026%	+$95.4M	0.99%	38
2022 Q1	$619K	Sell	2,372 -12	-0.5%	-$2.85K	0.01%	382
2021 Q4	$524K	Sell	2,384 -960	-29%	-$187K	﹤0.01%	415
2021 Q3	$607K	Sell	3,344 -14,188	-81%	-$2.77M	0.01%	387
2021 Q2	$3.54M	Sell	17,532 -30	-0.2%	-$6.28K	0.03%	179
2021 Q1	$3.77M	Buy	17,562 +4,609	+36%	+$1.01M	0.04%	160
2020 Q4	$3.06M	Buy	12,953 +5,737	+80%	+$1.32M	0.03%	160
2020 Q3	$1.96M	Sell	7,216 -544	-7%	-$150K	0.02%	177
2020 Q2	$2.25M	Buy	7,760 +613	+9%	+$166K	0.03%	159
2020 Q1	$1.7M	Buy	7,147 +1,841	+35%	+$422K	0.03%	170
2019 Q4	$1.16M	Buy	+5,306	New	+$1.07M	0.02%	240
2018 Q4	–	Sell	-46,397	Closed	-$8.94M	–	476
2018 Q3	$8.94M	Buy	46,397 +3,649	+9%	+$650K	0.12%	95
2018 Q2	$7.27M	Sell	42,748 -21,554	-34%	-$3.34M	0.09%	136
2018 Q1	$10.5M	Sell	64,302 -5,245	-8%	-$857K	0.13%	110
2017 Q4	$10.4M	Sell	69,547 -15,965	-19%	-$2.36M	0.13%	114
2017 Q3	$13M	Buy	85,512 +43,125	+102%	+$6.49M	0.17%	100
2017 Q2	$5.46M	Buy	+42,387	New	+$5.1M	0.08%	162

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Pendal Group's VRTX Position: Q4 2022 in Review

Pendal Group increased its Vertex Pharmaceuticals (VRTX) stake by 0.14% in Q4 2022, buying an estimated $130K and bringing the position to 297,723 shares worth $86M. The position accounts for 0.74% of the portfolio, ranked #48.

Pendal Group first reported a position in VRTX in Q2 2017 and has held it in 19 quarters since. The position peaked at $101M in Q2 2022. 1,222 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

Pendal Group held 297,723 shares of Vertex Pharmaceuticals worth $86M as of Q4 2022.
Pendal Group bought 425 Vertex Pharmaceuticals shares in Q4 2022, an estimated $130K.
Vertex Pharmaceuticals made up 0.74% of Pendal Group's portfolio in Q4 2022, its #48 holding.
Pendal Group first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 19 quarters since.
Pendal Group's Vertex Pharmaceuticals position peaked at $101M in Q2 2022.
1,222 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on Pendal Group's 13F filing for Q4 2022, filed 19 Jan 2023.